&#xa0;
[normal]Written evidence submitted by [bold]National Institute of Biological Standards and Control [bold](BTO00005)[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]December 2013
[normal]&#xa0;
[normal]Attachments
[normal]&#xa0;
[normal]&#xa0;
[normal]Dr Philip Minor (NIBSC,MHRA)
[normal]Professor Noel Gill (PHE) 
[normal]Dr Jillian Cooper (NIBSC, MHRA)
[normal]Professor Jean Manson (
[normal]Roslin
[normal] Institute)
[normal]Professor Richard Knight (CJDRSU)
[normal]Dr Simon Mead (MRC 
[normal]Prion
[normal] Unit)
[normal]Dr Neil Almond (NIBSC, MHRA) 
[normal]Dr David 
[normal]Anstee
[normal] (NHSBT)
[normal]Professor Robert Will (CJDRSU)
[normal]Dr Maurice 
[normal]Bardsley
[normal] (VLA) 
[normal]Dr Jim Hope (VLA)
[normal]Professor Christine Lee (Royal Free Hospital, retired)
[normal]Gill Turner (CJD Support Network)
[normal]Professor Marc Turner (NHSBT)
[normal] Professor Janet 
[normal]Darbyshire
[normal] (MRC, retired)
[normal]Dr 
[normal]Micha
[normal] 
[normal]Nuebling
[normal] (Paul Ehrlich Institute, Germany)
[normal]Dr Joliette 
[normal]Coste
[normal] (French Blood Transfusion Service)
[normal]Dr Stephen Lee (MHRA)
[normal]Dr Nick Andrews (PHE)
[normal]Mark 
[normal]Noterman
[normal] (DH)
[normal]Dr Gary 
[normal]Mallinson
[normal] (NHSBT)
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]Cooper, J.K., Andrews, N., 
[normal]Ladhani
[normal], K., 
[normal]Bujaki
[normal], E., &amp; Minor, P.D.. Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease. 
[normal]Vox
[normal] 
[normal]Sanguinis
[normal] 
[normal]2013, 105, (3) 196-204;   
[normal]Cooper, J.K., K. Ladhani, and P. Minor, Comparison of candidate vCJD in vitro diagnostic assays using identical sample sets
[normal].
[normal] 
[normal]Vox Sanguinis
[normal], 2012. 
[normal]102[bold](2): p. 100-9;  
[normal]J. K. Cooper, K. 
[normal]Ladhani
[normal] &amp; P. D. Minor Reference materials for the evaluation of pre-mortem variant Creutzfeldt–Jakob disease diagnostic assays 
[normal]Vox
[normal] 
[normal]Sanguinis
[normal] (2007) 
[normal]92[bold], 302–310
[normal]&#xa0;[bold]&#xa0;
[normal]The aim of the CJD resource centre and its oversight committee is to ensure fair and appropriate access to extremely rare blood components from clinical cases of 
[normal]vCJD
[normal].  Samples used in these studies were generated by NIBSC in collaboration with other TSE research groups who supplied animal samples (AHVLA and 
[normal]Roslin
[normal]); the CJD Surveillance unit and the MRC 
[normal]Prion
[normal] clinic who provided CJD samples and the UK National Blood and Transfusion Service who provided normal donor samples.  Both test sensitivity (how little infectious material can be detected) and specificity (number of samples incorrectly scored positive) studies were performed.  
[normal]Completed evaluation studies:
[normal]Company A
[normal]Samples  provided:
[normal]&#xa0;
[normal]Spiked panel sets (
[normal]vCJD
[normal] tissue homogenates in pooled human plasma
[normal]              
[normal]2006
[normal]48 samples)
[normal]Sheep plasma samples (
[normal]Scrapie
[normal], BSE infected and Control; total 250)
[normal]              
[normal]2008
[normal]UK blood donor plasma (1000 individuals, unfrozen, prepared 
[normal]              
[normal]              
[normal]2008
[normal]daily at NIBSC)
[normal]              
[normal]              
[normal]              
[normal]              
[normal]Primate plasma (BSE infected and controls; total 60)
[normal]              
[normal]              
[normal]              
[normal]2009
[normal]UK donor plasma (Frozen set, 1000 individuals)
[normal]              
[normal]              
[normal]              
[normal]              
[normal]2009
[normal]Variant and Sporadic CJD plasma (3 variant, 2 sporadic)
[normal]              
[normal]along
[normal]              
[normal]              
[normal]2009
[normal]With normal donor samples (500) 
[normal]              
[normal]              
[normal]&#xa0;
[normal]Complete evaluation was published in 2013:
[normal]&#xa0;
[normal]Cooper, J.K., et al., 
[normal]Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease.
[normal] Vox Sang, 2013. 
[normal]105[bold](3): p. 196-204.
[normal]&#xa0;
[normal]Company B
[normal]&#xa0;
[normal]&#xa0;
[normal]Spiked panel sets (
[normal]vCJD
[normal] tissue homogenates in pooled human plasma, 
[normal]              
[normal]2009
[normal]48 samples)
[normal]              
[normal]Sheep plasma samples (
[normal]Scrapie
[normal], BSE infected and Control; total 250)
[normal]              
[normal]2009
[normal]UK donor plasma (2000 samples, unfrozen (1000); frozen (1000)
[normal]              
[normal]              
[normal]2011
[normal]Variant CJD plasma (2 samples)
[normal]              
[normal]plus 200 normal US donor plasma 
[normal]              
[normal]2012
[normal]samples
[normal]              
[normal]              
[normal]              
[normal]              
[normal]              
[normal]&#xa0;
[normal]Other tests evaluated (research and commercial) 
[normal]9 groups provided with detergent-extracted plasma (48 samples)
[normal]              
[normal]2004
[normal]12 groups provided with spiked plasma panel (
[normal]cryo
[normal]-depleted
[normal]              
[normal]              
[normal]2006/2007
[normal] pooled plasma, 48 samples)
[normal]              
[normal]              
[normal]              
[normal]              
[normal]6 groups provided with spiked panel set using pooled whole plasma
[normal]              
[normal]2007/8/9/10
[normal]&#xa0;
[normal]Following evaluation of the blinded sample sets, problems with sensitivity, specificity and reproducibility were identified.  Results for these studies were published in 2012 in:
[normal]&#xa0;
[normal]Cooper, J.K., K. Ladhani, and P. Minor, 
[normal]Comparison of candidate vCJD in vitro diagnostic assays using identical sample sets.
[normal] Vox Sang, 2012. 
[normal]102[bold](2): p. 100-9.
[normal]&#xa0;
[normal]Research groups (X5) all still currently active
[normal]Spiked panel sets (
[normal]vCJD
[normal] tissue homogenates in pooled human plasma, total samples 24) 
[normal]              
[normal]2011/12
[normal]Sheep 
[normal]buffy
[normal] coat preparations (
[normal]scrapie
[normal] and control, 12 samples sent) to
[normal]              
[normal]              
[normal]              
[normal]2013
[normal]&#xa0;
[normal]Commercial developers (X1
[normal])
[normal]Spiked panel sets (
[normal]vCJD
[normal] tissue homogenates in human pooled plasma, total samples 24)
[normal]              
[normal]2013
[normal]&#xa0;[bold]&#xa0;
[normal]&#xa0;
[normal]